Healthcare inequalities in bone marrow transplants

Examining different treatment and diagnostic options for patients undergoing bone marrow transplant (BMT) is an important part of improving outcomes....

Visual abstract | Lenalidomide and Eltrombopag for Treatment in Low or Intermediate Risk Myelodysplastic Syndrome: Result of a Phase 2 Study Combination Clinical Trial

During the 63rd American Society...

Phase I results of venetoclax combined with azacitidine in high-risk MDS or CMML

During the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, Alexandre Bazinet1 presented phase...

What new treatments are available for high-risk MDS? What does this mean for patients?

During the 63rd ASH Annual Meeting and Exposition, the MDS Hub was pleased to speak to Andrew Brunner,...

Do mRNA-based COVID vaccines lead to adverse events in recently transplanted patients?

During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the MDS Hub...

EPICOVIDEHA registry: Epidemiology and outcomes in patients with hematologic malignancies infected with COVID-19

Patients with hematologic malignancies (HMs) may have intensified immune dysregulation...

Severity of SARS-CoV-2 infection and the safety of COVID-19 vaccination in patients receiving HSCT

The coronavirus pandemic has put a great strain on worldwide healthcare systems. Patients with...

Fungal superinfections and COVID-19 in the ICU

The COVID-19 pandemic has caused a worldwide healthcare crisis. In addition to the morbidity caused by the initial infection, severely ill patients are...

Anemia treatment with luspatercept in patients with lower-risk MDS: results from the PACE-MDS study

Luspatercept is a first-in-class erythroid-maturation agent approved by the FDA for the treatment of...

Visual abstract | Enasidenib as monotherapy and in combination with azacitidine for patients with IDH2-mutated MDS: results from a phase II study

A representaion of key data from a phase II clinical...

What patient factors should we consider for intermediate- and high-risk patients beyond the IPSS-R score?

The MDS Hub Steering Commitee met on May 5, 2022. The recorded discussion was chaired by Rena...

New IPSS-Molecular model for MDS risk stratification and prognosis

Bernard, et al. evaluated the combined prognostic power of hematologic, cytogenetic, and somatic gene mutation parameters in the...